nifedipine has been researched along with triazolam in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (17.39) | 18.2507 |
2000's | 10 (43.48) | 29.6817 |
2010's | 9 (39.13) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Mendelson, WB | 1 |
Mendelson, WB; Monti, D | 1 |
Kulkarni, SK; Reddy, DS | 1 |
Higuchi, H; Hishikawa, Y; Shimizu, T; Takahashi, H; Yoshimoto, M | 1 |
Cantrell, VE; Eckstein, J; Hall, SD; Hamman, MA; Jones, DR; Ring, BJ; Ruterbories, K; Williams, JA; Wrighton, SA | 1 |
Greenblatt, DJ; Patki, KC; Von Moltke, LL | 2 |
Amino, M; Inokuchi, S; Morita, S; Saito, T; Yamagiwa, T; Yamamoto, R | 1 |
Court, MH; Duan, SX; Greenblatt, DJ; Harmatz, JS; Parent, SJ; Venkatakrishnan, K; von Moltke, LL; Zhao, Y | 1 |
Baneyx, G; Iliadis, A; Lavé, T; Meille, C; Parrott, N | 1 |
Henderson, CJ; McLaughlin, LA; Scheer, N; Stanley, LA; Wolf, CR | 1 |
Kotegawa, T; Koya, Y; Machi, Y; Namiki, N; Shobu, Y; Uchida, S | 1 |
1 review(s) available for nifedipine and triazolam
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
22 other study(ies) available for nifedipine and triazolam
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Nifedipine blocks effects of triazolam injected into the dorsal raphe nucleus on sleep.
Topics: Animals; Body Temperature; Dose-Response Relationship, Drug; Electroencephalography; Electromyography; Male; Microinjections; Nifedipine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Sleep; Triazolam | 1994 |
Effects of triazolam and nifedipine injections into the medial preoptic area on sleep.
Topics: Animals; Body Temperature; Electroencephalography; Injections; Male; Nifedipine; Preoptic Area; Rats; Rats, Sprague-Dawley; Sleep; Sleep Stages; Triazolam | 1993 |
Differential anxiolytic effects of neurosteroids in the mirrored chamber behavior test in mice.
Topics: Animals; Anti-Anxiety Agents; Behavior, Animal; Calcium Channel Blockers; Dose-Response Relationship, Drug; Flumazenil; GABA Antagonists; GABA Modulators; Isoquinolines; Male; Mice; Mice, Inbred BALB C; Motor Activity; Nifedipine; Picrotoxin; Reaction Time; Steroids; Triazolam | 1997 |
Different effects of L-type and T-type calcium channel blockers on the hypnotic potency of triazolam and zolpidem in rats.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Calcium Channels, T-Type; Drug Interactions; Flunarizine; Hypnotics and Sedatives; Male; Nifedipine; Pyridines; Rats; Rats, Wistar; Sleep, REM; Triazolam; Zolpidem | 1999 |
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Topics: Alprazolam; Aryl Hydrocarbon Hydroxylases; Biotransformation; Clarithromycin; Coumarins; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Cytochromes b5; Diltiazem; Estradiol; Humans; In Vitro Techniques; Kinetics; Microsomes, Liver; Midazolam; Nifedipine; Tamoxifen; Testosterone; Triazolam | 2002 |
In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Ketoconazole; Microsomes, Liver; Midazolam; Nifedipine; Recombinant Proteins; Testosterone; Triazolam | 2003 |
Ethanol inhibits in-vitro metabolism of nifedipine, triazolam and testosterone in human liver microsomes.
Topics: Androgens; Anti-Anxiety Agents; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cells, Cultured; Cytochrome P-450 CYP3A; Drug Interactions; Ethanol; Humans; Hydroxylation; Microsomes, Liver; Nifedipine; Oxidoreductases, N-Demethylating; Testosterone; Triazolam; Vasodilator Agents | 2004 |
A case of torsades de pointes induced by severe QT prolongation after an overdose of eperisone and triazolam in a patient receiving nifedipine.
Topics: Anti-Anxiety Agents; Calcium Channel Blockers; Coma; Drug Interactions; Drug Overdose; Electrocardiography; Humans; Long QT Syndrome; Male; Middle Aged; Muscle Relaxants, Central; Nifedipine; Propiophenones; Torsades de Pointes; Triazolam | 2010 |
Mechanism of cytochrome P450-3A inhibition by ketoconazole.
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Humans; Inhibitory Concentration 50; Ketoconazole; Male; Microsomes, Liver; Midazolam; Middle Aged; Nifedipine; Testosterone; Triazolam; Young Adult | 2011 |
Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
Topics: Alfentanil; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Hepatocytes; Humans; Midazolam; Models, Biological; Nifedipine; Rifampin; Tissue Distribution; Triazolam | 2014 |
Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
Topics: Animals; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochromes b5; Debrisoquin; Ethanolamines; Female; Humans; Male; Mice, Knockout; Microsomes, Liver; Nifedipine; Sex Factors; Triazolam | 2015 |
Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs.
Topics: Administration, Oral; Adsorption; Aluminum Hydroxide; Amlodipine; Aspirin; Carbon; Drug Interactions; Glycine; Humans; Intestinal Absorption; Losartan; Magnesium; Metoprolol; Models, Biological; Nifedipine; Oxides; Renal Insufficiency, Chronic; Solubility; Triazolam | 2016 |